AC Immune (ACIU) Common Equity (2014 - 2026)

AC Immune (ACIU) has reported Common Equity for 13 consecutive years, with $40.3 billion the latest figure, recorded in Q1 2026.

• In Q1 2026, Common Equity rose 38091.77% year-over-year to $40.3 billion; the TTM figure through Mar 2026 stood at $40.3 billion (up 38091.77% YoY), while the FY2025 annual figure was $54.1 billion, up 42141.29% from the prior year.
• Common Equity retreated to $40.3 billion in Q1 2026 per ACIU's latest filing, from $56.2 billion in the prior quarter.
• Across five years, Common Equity topped out at $231.9 billion in Q1 2022 and bottomed at $78.1 million in Q3 2025.
• Historically, Common Equity has averaged $19.4 billion across 5 years, with a median of $165.3 million in 2023.
• Annual changes were most pronounced in 2023 — Common Equity sank 99.93% — and 2025, when it soared 43718.74%.
• AC Immune's Common Equity stood at $175.4 million in 2022, then rose by 3.24% to $181.1 million in 2023, then fell by 29.23% to $128.2 million in 2024, then jumped by 43718.74% to $56.2 billion in 2025, then dropped by 28.29% to $40.3 billion in 2026.
• Business Quant data shows ACIU's Common Equity at $40.3 billion in Q1 2026, $56.2 billion in Q4 2025, and $78.1 million in Q3 2025.